Belgian biotech UCB has made its second acquisition of the year, agreeing a front-loaded takeover of US biotech Candid ...

In 2022, obesity contributed just 1% of the projected value of pharma industry pipeline, as calculated by Deloitte. Now, its ...

After failing to muster sufficient support for an IPO last year, autoimmune and inflammatory disease specialist Odyssey ...

A digital therapy that could reduce the severity of chronic tic disorders like Tourette syndrome has been recommended for use by the NHS for the first time. The technology, known as ORBIT (Online ...

Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...

Over the past decade, neurodegenerative research and development has responsibly answered a foundational question: can we ...

In its first meeting for months, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against AstraZeneca's oral ...

Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscaled $300 million for its inhaled therapies for respiratory diseases. The company confirmed today it ...

The first data has emerged on the uptake of Novo Nordisk's new oral version of GLP-1 agonist weight-loss therapy Wegovy, with encouraging signs of strong demand as a potential rival from Eli Lilly ...

US MFN rules and new tariffs are narrowing the US–ex-US price gap and drawing more manufacturing and capital investment toward the United States. Low European or UK list prices now directly affect US ...

As a tech lover, I soak it all in and leave inspired about what’s next. This was the case recently when I attended Google ...